Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ALT
ALT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALT News
Altimmune Reports Q4 2025 Earnings and Phase III Trial Plans
4d ago
seekingalpha
Altimmune's Financial Status and Trial Progress
5d ago
stocktwits
Altimmune Announces Late-Stage Trial Plans for Pemvidutide
5d ago
seekingalpha
Altimmune (ALT) Q4 2025 Earnings Call Transcript
5d ago
NASDAQ.COM
Altimmune Q4 Earnings Report Analysis
5d ago
seekingalpha
Altimmune Scheduled to Announce Q4 Earnings on March 5
5d ago
seekingalpha
Altimmune to Participate in Multiple Investor Conferences
Mar 02 2026
Newsfilter
Analysis of Weight Loss Drug Market Prospects
Feb 26 2026
Fool
Altimmune to Report Q4 2025 Financial Results on March 5
Feb 26 2026
Newsfilter
Eli Lilly's Dominance in Obesity Drug Market Reinforced
Feb 23 2026
CNBC
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
Feb 18 2026
Yahoo Finance
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
Jan 29 2026
Newsfilter
Longevity Infrastructure Market Undergoes Structural Reset
Jan 29 2026
PRnewswire
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
Jan 29 2026
Newsfilter
Altimmune Announces $75 Million Stock Offering Amid Market Volatility
Jan 28 2026
Benzinga
Qorvo Shares Drop After Disappointing Earnings Guidance
Jan 28 2026
Benzinga
Show More News
